"These data are impressive," stated Markus Sperandio, M.D., professor of cardiovascular physiology and microvascular disorders at the Walter-Brendel-Center of Experimental Medicine, Munich, Germany, where he conducted the TMA studies evaluating OMS721. "OMS721 looks like a promising agent to prevent thrombus formation in the microcirculation. We are planning additional studies to refine the dosing and timing of administration of OMS721 in models across a wide range of thrombotic disorders.""We are pleased with these results and are excited to initiate the clinical program for OMS721," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The current treatment options for aHUS are limited and, when compared to those options, we believe that OMS721 carries marked advantages that will translate to significant patient benefits. We are eager to evaluate the drug product in aHUS patients, and we remain on track to begin Phase 1 clinical trials mid-year."
Omeros Announces Positive OMS721 Data In Model Of Thrombotic Microangiopathy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.